Parties d'ouvrages collectifs (1)
1.
Sculier, J.-P., Meuleman, N., Meert, A.-P., & Berghmans, T. (2014). Pulmonary malignancies. In T. Welte (Ed.), pulmonary complications of HIV: ERS Monograph, Vol. 66. PULMONARY COMPLICATIONS OF HIV (pp. 186-198). Charles Feldman, Eva Polverino and Julio A. Ramirez. Articles dans des revues avec comité de lecture (117)
1.
Delbart, W., Karfis, I., Vercruyssen, M., De Wind, R., Meuleman, N., Wimana, Z., Flamen, P., & Woff, E. (2025). The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma. European journal of nuclear medicine and molecular imaging. doi:10.1007/s00259-025-07500-y2.
Delbart, W., Vercruyssen, M., Danieli, R., Marin, C., Wimana, Z., Meuleman, N., Flamen, P., Woff, E., & Karfis, I. (2025). First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma. EJNMMI reports, 9(1), 26. doi:10.1186/s41824-025-00262-83.
Van Morckhoven, D., Dubois, N., Bron, D., Meuleman, N., Lagneaux, L., & Stamatopoulos, B. (2023). Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment. Frontiers in immunology, 14, 1265969. doi:10.3389/fimmu.2023.12659694.
Draguet, F., Dubois, N., Bouland, C., Pieters, K., Bron, D., Meuleman, N., Stamatopoulos, B., & Lagneaux, L. (2023). Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stromal Cells as an Efficient Nanocarrier to Deliver siRNA or Drug to Pancreatic Cancer Cells. Cancers, 15(11), 2901. doi:10.3390/cancers151129015.
Draguet, F., Bouland, C., Dubois, N., Bron, D., Meuleman, N., Stamatopoulos, B., & Lagneaux, L. (2023). Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Natural Nanocarriers: Concise Review. Pharmaceutics, 15(2). doi:10.3390/pharmaceutics150205586.
Massaro, F., Corrillon, F., Stamatopoulos, B., Dubois, N., Ruer, A., Meuleman, N., Bron, D., & Lagneaux, L. (2023). Age-related changes in human bone marrow mesenchymal stromal cells: morphology, gene expression profile, immunomodulatory activity and miRNA expression. Frontiers in immunology, 14, 1267550. doi:10.3389/fimmu.2023.12675507.
Bouhtit, F., Najar, M., Rahmani, S., Melki, R., Najimi, M., Sadki, K., Boukhatem, N., Twizere, J.-C., Meuleman, N., Lewalle, P., Lagneaux, L., & Merimi, M. (2022). Bioscreening and pre-clinical evaluation of the impact of bioactive molecules from Ptychotis verticillata on the multilineage potential of mesenchymal stromal cells towards immune- and inflammation-mediated diseases. Inflammation research, 71(7-8), 887-898. doi:10.1007/s00011-022-01573-38.
Massaro, F., Meuleman, N., Bron, D., Vercruyssen, M., & Maerevoet, M. (2022). Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis. Cancers (Basel), 14(4), 982. doi:10.3390/cancers140409829.
Vekemans, M.-C., Doyen, C., Caers, J., Wu, K. L., Kentos, A., Mineur, P., Michaux, L., Delforge, M., & Meuleman, N. (2022). Recommendations on the management of multiple myeloma in 2020. Acta Clinica Belgica (English ed. Printed), 77(2), 445-461. doi:10.1080/17843286.2020.186041110.
Merimi, M., El-Majzoub, R., Lagneaux, L., Moussa Agha, D., Bouhtit, F., Meuleman, N., Fahmi, H., Lewalle, P., Fayyad Kazan, M., & Najar, M. (2021). The Therapeutic Potential of Mesenchymal Stromal Cells for Regenerative Medicine: Current Knowledge and Future Understandings. Frontiers in Cell and Developmental Biology, 9. doi:10.3389/fcell.2021.66153211.
Bouland, C., Philippart, P., Dequanter, D., Corrillon, F., Loeb, I., Bron, D., Lagneaux, L., & Meuleman, N. (2021). Cross-Talk Between Mesenchymal Stromal Cells (MSCs) and Endothelial Progenitor Cells (EPCs) in Bone Regeneration. Frontiers in Cell and Developmental Biology, 9, 674084. doi:10.3389/fcell.2021.674084